

Appendix 38 - PROSTATE CANCER

Approved settings/ treatment		Drugs in	
line	Protocols	abbreviation	Evidence level
Localized Disease (N0, M0) PSA Resistant/Recurrent	LHRH Agonists (Goserlin, Triptorelin,		
	Leuprolide).		Category 2A
	LHRH Agonist + 1st Anti androgen		
	(Flutamide, Bicalutamide, Nilutamide)		Category 2A
	LHRH Antagonist (Degarelix)		Category 2A
	LHRH Agonists (Goserlin, Triptorelin,		
	Leuprolide).		Category 2A
Regional Disease (N1)	LHRH Agonist + 1st Anti androgen		
	(Flutamide, Bicalutamide, Nilutamide)		Category 2A
	LHRH Antagonist (Degarelix)		Category 2A
	LHRH Agonists + Abiraterone.		Category 2B
	LHRH Antagonist + Abiraterone.		Category 2A
	Orchiectomy + Abiraterone.		Category 2A
	LHRH Agonist ± Docetaxel.		Category 2A
	LHRH Agonist + 1ST Anti-androgen ±		
Metastatic, Castration Naïve	Docetaxel.		Category 2A
	LHRH Antagonist ± Docetaxel.		Category 2A
	Orchiectomy ± Docetaxel.		Category 2A
	LHRH Agonist + Abiraterone, Enzalutamide.		Category 2A
	LHRH Antagonist + Abiraterone,		
	Enzalutamide.		Category 2A
	Orchiectomy + Abiraterone, Enzalutamide.		Category 2A
<u> </u>	2nd Anti-Androgen (Enzalutamide).		Category 2A
	Abiraterone + Prednisone.		Category 2A
Metastatic, Castration resistant	Ketoconazole.		Category 2A
	Ketoconazole + Hydrocortisone.		Category 2A
	1st Anti-androgen (Flutamide, Bicalutamide,		,
	Nilutamide)		Category 2A
	Corticosteroids (Prednisone,		,
	Hydrocortisone, Dexamethasone).		Category 2A
	Di-Ethyl Stilbestrol (DES)		Category 2A
Metastatic, Castration naïve	Docetaxel + ADT + Dexamethasone		Category 2A
Metastatic, Castration resistant	Docetaxel + Dexamethasone or prednisone		Category 2A
Wetastatic, Castration resistant	Cabazitaxel + Dexamethasone or prednisone		Category 2A
	Mitoxantrone + Prednisone		Category 2A
	Pembrolizumab		Category 2A
	Olaparib regimens		Category 2A
	Olapano regimeno		Category 271